BriaCell presents clinical efficacy data from Phase 2 Bria-IMT study

BriaCell Therapeutics announces positive clinical efficacy data updates of its ongoing randomized Phase 2 study evaluating lead clinical candidate Bria-IMT(TM) in patients with advanced metastatic breast cancer. Two poster sessions, one abstract, and one oral presentation session will be presented at the 2024 American Society of Clinical Oncology Annual Meeting taking place today June 3, 2024 at McCormick Place, Chicago, IL. “Our ASCO presentations highlight how Bria-IMT(TM)’s activities – through diverse mechanisms including adaptive and innate responses – synergize with multiple mechanisms of action of checkpoint inhibitors,” stated Dr. Williams, BriaCell’s President and CEO. “We believe Bria-IMT(TM) has the potential to become a breakthrough novel treatment option for patients in advanced metastatic breast cancer.” “We are very impressed with both clinical efficacy and safety data in these heavily pretreated patients. Given the limited effective treatment options in this group of patients, and the fact that most treatments are associated with significant toxicities, physicians and patients often opt to decline further ineffective and toxic drugs in lieu of palliative care,” Saranya Chumsri, MD, Principal Investigator and Professor of Oncology, Mayo Clinic. “Antibody-drug conjugates and immune checkpoint Inhibitors have emerged as the latest therapies to treat these patients. However, a large percentage of late-stage patients do not respond, and all patients inevitably develop resistance to them, making a safe and effective treatment an urgent medical need. BriaCell’s novel immunotherapy offers a well-tolerated treatment option for these patients beyond the currently approved drugs.”